A phase II, 20-week, multi-centre, randomised, double-blind, placebo-controlled, parallel group proof of concept study to investigate the efficacy and safety of GSK1605786 for treatment of patients with active Ulcerative Colitis (CCX115393) - CCX115393
BEL114674: A 2 year study of efficacy and safety of intravenous belimumab versus placebo in subjects with idiopathic membranous nephropathy - BEL114674
An open label, experimental medicine investigation of the safety and tolerability of 400 mg b.i.d. GSK2586184 in patients with moderate to severely active ulcerative colitis (200208) - 200208 (JAK)
100 项与 GlaxoSmithkline BV 相关的临床结果
0 项与 GlaxoSmithkline BV 相关的专利（医药）
100 项与 GlaxoSmithkline BV 相关的药物交易
100 项与 GlaxoSmithkline BV 相关的转化医学
